Komori
Ono Pharmaceutical (4528) · InitiativeIncrease in investment in research facilities

Investment to Expand and Maintain Research Facilities

First written in FY2016. 2 of 9 entries say "Restated". Latest entry: FY2025.

9entries
10years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseOtherFY2016 – FY20252016: 120162017: 120172018: 120182019: 020192020: 120202021: 120212022: 120222023: 120232024: 120242025: 12025
Same theme, other companies
Capital investment to enhance analytical and research and development capabilitiesA theme 3 companies write about · 0 as a headwind · 3 as a tailwind

1 other company's latest entry also says "Other".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2025Increase in investment in research facilitiesAnnual report

    「We invested a total of ¥8,061 million, including ¥3,854 million in research equipment expansion and maintenance, ¥2,763 million in sales equipment and other expansion and maintenance, and ¥1,444 million in production equipment expansion and maintenance.」

    Research equipment investment increased from ¥3,422 million in the previous fiscal year to ¥3,854 million, and investment in the research platform continued.
  2. FY2024Decrease in investment in research facilitiesAnnual report

    「During the fiscal year under review, we invested a total of ¥6,493 million, including ¥3,422 million in research equipment expansion and maintenance, ¥2,238 million in sales equipment and other expansion and maintenance, and ¥833 million in production equipment expansion and maintenance.」

    Research equipment investment decreased from ¥4,063 million in the previous fiscal year to ¥3,422 million, while investment in research equipment itself continued.
  3. FY2023Decrease in investment in research facilitiesAnnual report

    「During the consolidated fiscal year, a total of ¥7,725 million was invested in capital expenditures, including ¥4,063 million in the expansion and maintenance of research facilities, ¥2,232 million in sales facilities and other assets, and ¥1,430 million in production facilities.」

    Research equipment investment continued, but decreased from ¥5,247 million in the previous fiscal year to ¥4,063 million.
  4. FY2022Decrease in investment in research facilitiesAnnual report

    「During the consolidated fiscal year, a total of ¥9,336 million was invested in capital expenditures, including ¥5,247 million in the expansion and maintenance of research facilities, ¥2,858 million in sales facilities and other assets, and ¥1,231 million in production facilities.」

    Investment in research facilities continued, but the amount decreased from ¥6,029 million in the previous fiscal year to ¥5,247 million.
  5. FY2021Increase in investment in research facilitiesAnnual report

    「During the consolidated fiscal year, a total of ¥9,100 million was invested in capital expenditures, including ¥6,029 million in the expansion and maintenance of research facilities, ¥1,568 million in production facilities, and ¥1,503 million in sales facilities and other assets.」

    Investment in research facilities increased from ¥1,881 million in the previous fiscal year to ¥6,029 million, expanding investment in the research infrastructure.
  6. FY2020Decrease in investment in research facilitiesAnnual report

    「During the consolidated fiscal year, a total of ¥9,520 million was invested in capital expenditures, including ¥4,475 million in the expansion and maintenance of production facilities, ¥3,164 million in sales facilities and other assets, and ¥1,881 million in research facilities.」

    Investment in the expansion and maintenance of research facilities continued, but the amount fell from ¥6,496 million in the previous fiscal year to ¥1,881 million.
  7. FY2018RestatedAnnual report

    「During the consolidated fiscal year, a total of ¥18,593 million was invested in capital expenditures, including ¥6,496 million in the expansion and maintenance of research facilities, ¥6,227 million in production facilities, and ¥5,870 million in sales facilities and other assets.」

    Capital expenditures, including research facilities, continued, reaffirming the investment policy for the research and production infrastructure.
  8. FY2017RestatedAnnual report

    「During the consolidated fiscal year, a total of ¥9,532 million was invested in capital expenditures, including ¥4,892 million in the expansion and maintenance of research facilities, ¥3,341 million in production facilities, and ¥1,299 million in sales facilities and other assets.」

    Capital expenditures, including investment in the expansion and maintenance of research facilities, were made during the period, reaffirming the investment policy for the research infrastructure.
  9. FY2016First statedAnnual report

    「A total of ¥15,771 million was invested, including ¥1,107 million in the expansion and maintenance of production facilities, ¥10,570 million in research facilities, and ¥4,094 million in sales facilities and other assets. / 2016: Building 3 of the Minase Research Institute was completed.」

    The ¥10,570 million investment in research facilities and completion of Building 3 of the Minase Research Institute are described as development of the research infrastructure.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Ono Pharmaceutical's next results are scheduled for 2026-10-29. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Investment to Expand and Maintain Research Facilities | ONO PHARMACEUTICAL CO.,LTD. (4528) | Komori